Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Conditions
Interventions
Durvalumab
Tremelimumab
Locations
6
United States
Yale Cancer Center
New Haven, Connecticut, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Mary Crowley Cancer Research Center
Dallas, Texas, United States
University of Virginia Division of Hematology and Oncology
Charlottesville, Virginia, United States
Start Date
December 19, 2013
Primary Completion Date
December 1, 2019
Completion Date
July 2, 2021
Last Updated
October 12, 2022
NCT07446322
NCT07547774
NCT07040891
NCT06257264
NCT06964009
NCT07541924
Lead Sponsor
Ludwig Institute for Cancer Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions